期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗血管生成治疗头颈部鳞状细胞癌的研究进展 被引量：1

Progress on anti-angiogenesis treating head and neck squamous cell carcinoma
原文传递
导出
摘要 目前对于复发或转移头颈部鳞状细胞癌（HNSCC）以姑息性化疗及EGFR靶向治疗为主,肿瘤血管的形成是肿瘤生长和远处转移的关键因素，因此，促进血管生成的因子及其受体成为靶向治疗的靶点，目前抗血管生成药物主要通过阻断VEGF-VEGF受体（VEGFR）通路，其在治疗HNSCC的临床试验中取得一定效果，为治疗HNSCC提供更多选择。 Current treatment strategies for recurrent or metastatic head and neck squamous cell carcinoma（HNSCC） include palliative chemotherapy and antiEGFR targeted agents. Angiogenesis is crucial both for the growth of a primary tumor and the development of distant metastasis. Therefore, the angiogenesis factors and their receptors become the targets of therapeutic agents. Current antiangiogenesis drugs achieve the purpose of treatment mainly by blocking VEGF-VEGFR pathways. And it gets certain effects in clinical trials for the treatment of HNSCC. Antiangiogenesis therapy will provide more choices for treating HNSCC.
作者 尚艺泰 李晓江
机构地区 昆明医科大学第三附属医院头颈外科云南省头颈肿瘤研究中心
出处 《国际肿瘤学杂志》 CAS 2015年第8期619-621,共3页 Journal of International Oncology
关键词 头颈部肿瘤 血管生成抑制剂 血管内皮生长因子A Head and neck neoplasms Angiogenesis inhibitors Vascular endothelial growth factor A
分类号 R739.91 [医药卫生—肿瘤]
  • 相关文献

参考文献19

  • 1FerlayJ, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008[J]. IntJ Cancer, 2010, 127 (12) :2893-2917.
  • 2de Mello RA, Gems S, Alves MP, et al. Cetuximab plus platinum?based chemotherapy in head and neck squamous cell carcinoma: a ret?rospective study in a single comprehensive European cancer institution[J]. PLoS One, 2014, 9(2) :e86697.
  • 3Argiris A, Karamouzis MV, Gooding WE, et al. Phase n trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancerlJ}.J Clin Oncol, 2011,29(9) :1140-1145.
  • 4Fury MG, Lee NY, Sherman E, et al. A phase 2 study of hevacizum?ab with cisplatin plus intensity-modulated radiation therapy for stage m/NB head and neck squamous cell cancer[J]. Cancer, 2012, 118 (20) :5008-5014.
  • 5Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizum?ab : preclinical data and phase n trial in recurrent or metastatic squa?mous cell carcinoma of the head and neck[J]. Ann Oncol, 2013 , 24 (1) :220-225.
  • 6Y 00 DS, KirkpatrickJP, Craciunescu 0, et al. Prospective trial of synchronous bevacizumab, erlotinib, and concurrent chemoradiation in locally advanced head and neck cancer[J]. Clin Cancer Res, 2012,18(5) :1404-1414.
  • 7MachielsJP, Henry S, Zanetta S, et al. Phase Il study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006'f)1[J].J Clin Oncol, 2010, 28 (1 ) :21-28.
  • 8Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase Il study of sunitinib in patients with recurrent andl or metastatic non?nasopharyngeal head and neck cancer[J]. Cancer Chemother Phar?macol, 2010, 65(4) :649-660.
  • 9Choong NW, Kozloff M, Taber D, et al. Phase Il study of sunitinib malate in head and neck squamous cell carcinoma[J]. Invest New Drugs, 2010, 28 (5) :677 -683.
  • 10Williamson SK, MoonJ, Huang CH, et al. Phase n evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: southwest oncology group study 50420[J].J Clin Onool , 2010, 28(20) :3330-3335.

二级参考文献13

  • 1姚鸿超 ,金德均 ,孙亚男 ,任明华 ,李晓丹 .内皮抑素治疗人喉癌裸鼠模型的实验研究[J].中华耳鼻咽喉科杂志,2004,39(7):394-398. 被引量：13
  • 2刘秀峰,秦叔逵,王琳,钱军,陈映霞,何泽明,龚新雷,杨柳青.恩度与化疗联合治疗多种晚期恶性肿瘤的临床观察[J].临床肿瘤学杂志,2007,12(4):241-245. 被引量：144
  • 3Agarwala SS.Adjuvant Chemotherapy in head and neck Cancer[J].Hematol Oncol Clin North Am,1999,13(4):743-752.
  • 4Cohen EE,Rosen F,Stadler WM,et al.Phase Ⅱ trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck[J].J Clin Oncol,2003,21(10):1980-1987.
  • 5Soulieres D,Senzer NN,Vokes EE,et al.Multicenter phase Ⅱ study of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck[J].J Clin Oncol,2004,22 (1):77-85.
  • 6Baselga J,Trigo JM,Bourhis J,et al.Phase Ⅱ multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck[J].J Clin Oncol,2005,23(24):5568-5577.
  • 7Leon X,Hitt R,Constenla M,et al.A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy[J].Clin Oncol (R Coll Radiol),2005,17(4):418-422.
  • 8Folkman J.Tumor angiogenesis:therapeutic implications[J].N Engl J MED,1971,285(21):1182-1186.
  • 9O'Reilly MS,Boehm T,Shing Y,et al.Endostatin:an endogenous inhibitor of angiogenesis and tumor growth[J].Cell,1997,88 (2):277-285.
  • 10Wilson BF,Morse MA,Pei P,et al.Endostatin inhibits migration and invasion of head and neck squamous cell carcinoma cells[J].Anticancer Res,2003,23 (2B):1289-1295.

共引文献1

同被引文献17

引证文献1

国际肿瘤学杂志
2015年 第8期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部